GSK Pharma hits 3-month high in weak market; surges 32% in 7 days
The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...
portfolio-adviser.com1h
GlaxoSmithKline begins £2bn share buyback programme
It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...
GSK completes GBP1 billion IDRx purchase; starts GBP2 billion buyback
GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.
Daily2h
Dr Gavin Screaton to join Board of GSK as Non-Executive Director
On appointment, Dr Screaton will become a member of the GSK Board Science Committee and the Corporate Responsibility ...
GSK Eyes Growth in Cancer Drugs Amid Investor Pipeline Concern
GSK Plc is looking to further grow its cancer drug business, a senior executive said, after the drugmaker’s $1.15 billion ...
Daily3h
Syngene International gets 5 USFDA observations for Bengaluru facilities
Bengaluru: Syngene International has announced that the U.S. Food and Drugs Administration (USFDA) has concluded the ...
Taiwan News10h
Hereditary Angioedema Therapeutic Market to Exceed USD 4.42 Billion, Projected 8.5%+ CAGR Through 2030
Global Hereditary Angioedema Therapeutic Market is valued at approximately USD 4.42 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period ...